Psychiatry

The first quarter of 2025 saw approvals in diabetes, depression, kidney disease, and pain, among others. Read more about high-impact approvals of Q1 now.

TSND-201 (methylone) met its primary endpoint in the phase 2 IMPACT-1 trial, showing rapid, significant PTSD symptom improvement with a good safety profile.

A study links daily discrimination to greater depression and anxiety rates, with marginalized groups facing greater mental health risks across the US.

A 2024 survey finds that most healthcare providers believe quality of life should be considered as much as symptom control when managing bipolar I disorder and schizophrenia.

A meta-analysis of 27 trials found no increased risk of suicide or self-harm with GLP-1 RAs, supporting their safety for diabetes and obesity management.

A Q2 2025 preview spotlighting 10 FDA decisions to watch, including upcoming PDUFAs for dupilumab, pz-cel, ketamine, clesrovimab, and more!

Axsome’s phase 3 trial shows solriamfetol significantly improves ADHD symptoms, with a 45% mean reduction in AISRS scores and onset as early as week 1.

A study highlights how food allergies impact adults' mental health and social lives, revealing anxiety, isolation, and the need for better support systems.

Our top 5 headlines featured an oral drug delivering 16% weight loss, notable blood pressure reductions from a hypertension treatment, and 3 key FDA decisions.

Liver transplants for alcohol-associated liver disease and alcohol-associated hepatitis have increased, but many centers lack necessary resources for care.

With a new FDA goal date in June, ketamine is one step closer to receiving approval for anesthesia, sedation, pain, mental health, and neurological indications.

This month in review covers key psychiatry updates, including the latest FDA decisions, antidepressant use in pregnancy, and the latest episode of Medical Ethics Unpacked.

Our top 5 headlines include an FDA approval, a pair of submissions, data from AAAAI 2025, and more!

This FDA News Month in Review provides a round-up of regulatory decisions from February 2025.

Teva and Medincell announced FDA acceptance of their sNDA for UZEDY, a risperidone extended-release injectable, to treat adults with bipolar I disorder.

FDA approves expanded use of buprenorphine extended-release injection for opioid use disorder, adding new injection sites and reducing treatment induction time.

A phase 2b trial showed that, unlike patients with MDD, patients with treatment-resistant depression do not receive significant benefits from SPN-820.

A study found a strong link between headache disorders and suicide risk, including tension-type headaches.

A new study found antidepressant use drops by nearly 50% during pregnancy, but without increased psychotherapy, raising concerns about untreated depression risks.

Drs. Levine and Sisti discuss the ethical challenges of GLP-1 drug allocation, exploring fairness, disparities, and policy solutions for obesity and diabetes treatment.

This Month in Review highlights the top psychiatry news in January.

The trend warrants attention, given treatment difficulties and the association with other substance use issues, says lead author of Rutgers Health study.

Children who have had a stroke, especially in late primary school, face a greater r risk of anxiety, a study found.

GH Research's phase 2b trial found GH001, an inhalable 5-MeO-DMT treatment, led to a -15.5 MADRS score reduction by day 8 in patients with treatment-resistant depression.

This FDA News Month in Review provides a round-up of regulatory decisions and submissions from January 2025.